491 related articles for article (PubMed ID: 29381843)
1. Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.
Gottenberg JE; Dörner T; Bootsma H; Devauchelle-Pensec V; Bowman SJ; Mariette X; Bartz H; Oortgiesen M; Shock A; Koetse W; Galateanu C; Bongardt S; Wegener WA; Goldenberg DM; Meno-Tetang G; Kosutic G; Gordon C
Arthritis Rheumatol; 2018 May; 70(5):763-773. PubMed ID: 29381843
[TBL] [Abstract][Full Text] [Related]
2. Epratuzumab for the treatment of systemic lupus erythematosus.
Geh D; Gordon C
Expert Rev Clin Immunol; 2018 Apr; 14(4):245-258. PubMed ID: 29542345
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
Clowse ME; Wallace DJ; Furie RA; Petri MA; Pike MC; Leszczyński P; Neuwelt CM; Hobbs K; Keiserman M; Duca L; Kalunian KC; Galateanu C; Bongardt S; Stach C; Beaudot C; Kilgallen B; Gordon C;
Arthritis Rheumatol; 2017 Feb; 69(2):362-375. PubMed ID: 27598855
[TBL] [Abstract][Full Text] [Related]
4. Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases.
Steinfeld SD; Youinou P
Expert Opin Biol Ther; 2006 Sep; 6(9):943-9. PubMed ID: 16918261
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus.
Rao V; Gordon C
Immunotherapy; 2014; 6(11):1165-75. PubMed ID: 25496332
[TBL] [Abstract][Full Text] [Related]
6. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
7. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.
Wallace DJ; Kalunian K; Petri MA; Strand V; Houssiau FA; Pike M; Kilgallen B; Bongardt S; Barry A; Kelley L; Gordon C
Ann Rheum Dis; 2014 Jan; 73(1):183-90. PubMed ID: 23313811
[TBL] [Abstract][Full Text] [Related]
9. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.
Dörner T; Kaufmann J; Wegener WA; Teoh N; Goldenberg DM; Burmester GR
Arthritis Res Ther; 2006; 8(3):R74. PubMed ID: 16630358
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up.
Wallace DJ; Gordon C; Strand V; Hobbs K; Petri M; Kalunian K; Houssiau F; Tak PP; Isenberg DA; Kelley L; Kilgallen B; Barry AN; Wegener WA; Goldenberg DM
Rheumatology (Oxford); 2013 Jul; 52(7):1313-22. PubMed ID: 23542611
[TBL] [Abstract][Full Text] [Related]
11. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study.
Steinfeld SD; Tant L; Burmester GR; Teoh NK; Wegener WA; Goldenberg DM; Pradier O
Arthritis Res Ther; 2006; 8(4):R129. PubMed ID: 16859536
[TBL] [Abstract][Full Text] [Related]
12. The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus.
Dörner T; Shock A; Goldenberg DM; Lipsky PE
Autoimmun Rev; 2015 Dec; 14(12):1079-86. PubMed ID: 26212727
[TBL] [Abstract][Full Text] [Related]
13. IgA and IgG autoantibodies against alpha-fodrin as markers for Sjögren's syndrome. Systemic lupus erythematosus.
Witte T; Matthias T; Arnett FC; Peter HH; Hartung K; Sachse C; Wigand R; Braner A; Kalden JR; Lakomek HJ; Schmidt RE
J Rheumatol; 2000 Nov; 27(11):2617-20. PubMed ID: 11093442
[TBL] [Abstract][Full Text] [Related]
14. Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.
Rossi EA; Goldenberg DM; Michel R; Rossi DL; Wallace DJ; Chang CH
Blood; 2013 Oct; 122(17):3020-9. PubMed ID: 23821660
[TBL] [Abstract][Full Text] [Related]
15. Epratuzumab for systemic lupus erythematosus.
Wallace DJ; Goldenberg DM
Lupus; 2013 Apr; 22(4):400-5. PubMed ID: 23553783
[TBL] [Abstract][Full Text] [Related]
16. B cell depletion in lupus and Sjögren's syndrome: an update.
Coca A; Sanz I
Curr Opin Rheumatol; 2009 Sep; 21(5):483-8. PubMed ID: 19644378
[TBL] [Abstract][Full Text] [Related]
17. Sjögren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjögren's syndrome.
Manoussakis MN; Georgopoulou C; Zintzaras E; Spyropoulou M; Stavropoulou A; Skopouli FN; Moutsopoulos HM
Arthritis Rheum; 2004 Mar; 50(3):882-91. PubMed ID: 15022331
[TBL] [Abstract][Full Text] [Related]
18. Anti-agalactosyl IgG antibodies and isotype profiles of rheumatoid factors in Sjögren's syndrome and rheumatoid arthritis.
Ichikawa Y; Yamada C; Horiki T; Hoshina Y; Uchiyama M; Yamada Y; Toumatu J
Clin Exp Rheumatol; 1998; 16(6):709-15. PubMed ID: 9844764
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study.
Tsuru T; Tanaka Y; Kishimoto M; Saito K; Yoshizawa S; Takasaki Y; Miyamura T; Niiro H; Morimoto S; Yamamoto J; Lledo-Garcia R; Shao J; Tatematsu S; Togo O; Koike T
Mod Rheumatol; 2016; 26(1):87-93. PubMed ID: 26382733
[TBL] [Abstract][Full Text] [Related]
20. Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.
Chang CH; Wang Y; Gupta P; Goldenberg DM
MAbs; 2015; 7(1):199-211. PubMed ID: 25484043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]